Merck Cozaar, Bristol Avapro Gain Nephropathy Indication On Shared Data

FDA approvals of Merck's Cozaar (losartan) and Bristol/Sanofi's Avapro (irbesartan) for the treatment of nephropathy in type 2 diabetes patients are based on data shared by the companies under a reciprocal agreement